Baroness Delyth Morgan, CEO of Breast Cancer Now, tells us about some of the things she's been part of in her 25 years with the charity, as well as how we are focusing more on people with secondary breast cancer.
We’re committed to improving treatment, care and services for people living with secondary breast cancer, which is why it’s a central part of our new strategy.
Today, we are excited to announce that we have finally secured a long-overdue secondary breast cancer audit in England, delivering on one of the key calls from our Unsurvivors campaign.
In 2017, Jen received a de novo diagnosis of secondary breast cancer after experiencing some unusual symptoms. She tells us about the misconceptions she had about cancer, and how she's working with Breast Cancer Now to campaign for change.
The experiences of people living with secondary breast cancer are unique, which is why our secondary breast cancer campaign has been calling for these experiences to be acknowledged and understood.
A new targeted drug for treating breast cancer that has spread has been approved by the National Institute for Health and Care Excellence (NICE) for use on the Cancer Drugs Fund.
Our 2019 report, which looked at the experiences of over 2,000 people living with secondary breast cancer, found that many were experiencing avoidable delays in diagnosis.
Our Policy team have an update on the ongoing NICE methods and process review, and how we’re helping to ensure the system works for breast cancer drugs.
Drugs are a cornerstone of treatment for breast cancer. We know that you may have questions about drug treatment following the transition period ending on 31 December 2020. We take a look at what this means for medicines supply, medicines licensing, and clinical trials.